Ray Therapeutics' mission is to restore vision in patients with retinitis pigmentosa and other degenerative retinal disorders with our novel optogenetics approach.
Location: United States, California, San Diego
Employees: 1-10
Total raised: $110M
Founded date: 2021
Investors 2
| Date | Name | Website |
| 17.05.2023 | MRL Ventur... | mrlv.com |
| 21.05.2023 | Norwest Ve... | nvp.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.11.2023 | Grant | $4M | - |
| 02.06.2023 | Series A | $100M | - |
| 04.01.2022 | Seed | $6M | - |
Mentions in press and media 24
| Date | Title | Description |
| 25.04.2025 | Ray Therapeutics: $8 Million CIRM Grant Awarded | Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision restoration, announced it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM). This grant will suppor... |
| 19.11.2024 | C Ray Therapeutics: A New Dawn in Radiopharmaceuticals | In the bustling landscape of biotechnology, C Ray Therapeutics has emerged as a beacon of innovation. This Chengdu-based startup recently completed a Series A+ funding round, raising over $100 million. The investment was co-led by Shenzhen ... |
| 18.11.2024 | C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital | CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise in the field of radiopharmaceuticals, announced the completion o... |
| 18.11.2024 | C Ray Therapeutics Completes Over $100M Series A+ Financing | C Ray Therapeutics, a Chengdu, China-based enterprise in the field of radiopharmaceuticals, raised over $100M in Series A+ funding. The round was led by Shenzhen Capital Group Co., Ltd.’s Manufacturing Transformation and Upgrading New Mater... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 13.11.2023 | Ray Therapeutics Receives $4M Grant | Ray Therapeutics, a San Francisco, CA-based optogenetics company, received a $4M grant. California Institute for Regenerative Medicine awarded the grant. The company intends to use the funds to support development of RTx-021, an optogenetic... |
| 13.11.2023 | Ray Therapeutics secures $4M from CIRM to develop optogenetic therapy treatment for geographic atrophy | Age-related macular degeneration (AMD) is a prevalent cause of vision loss among individuals over the age of 65 globally. Over 18 million people in the United States alone are estimated to have milder forms of AMD, with a substantial portio... |
| 02.06.2023 | Ray Therapeutics: Leading Optogenetics Company Secures $100 Million | Ray Therapeutics – a leading optogenetics company – announced an upsized oversubscribed $100 million Series A financing round led by Novo Holdings A/S and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund... |
| 18.05.2023 | 4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing | - Ray Therapeutics Closes Oversubscribed $100M Series A Financing |
| 16.05.2023 | Ray Therapeutics Closes $100M Series A Financing | Ray Therapeutics, a San Francisco, CA-based optogenetics company, raised $100M in Series A funding. The round was led by Novo Holdings A/S, and joined by Deerfield Management, Norwest Venture Partners, Platanus, MRL Ventures Fund, and exist... |
Show more